gabrielle samuel

Dr. gabrielle samuel

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2022 in Sustainability
Verified
Journal Article
Open access
GSgabrielle samuel
gabrielle samuel
FLFederica Lucivero
Federica Lucivero
LCLucas Somavilla Croxatto
Lucas Somavilla Croxatto
Artificial Intelligence and associated digital technologies (DTs) have environmental impacts. These include heavy carbon dioxide emissions linked to the energy consumption required to generate and process large amounts of data; extracting minerals for, and manufacturing of, technological components; and e-waste. These environmental impacts are receiving increasing policy and media attention through discourses of environmental sustainability. At the same time, ‘sustainability’ is a complex and nebulous term with a multiplicity of meanings and practices. This paper explores how experts working with DTs understand and utilise the concept of environmental sustainability in their practices. Our research question was how do stakeholders researching, governing or working on the environmental impacts of DTs, utilise environmental sustainability concepts? We applied a combination of bibliometric analysis and 24 interviews with key stakeholders from the digital technology sector. Findings show that, although stakeholders have broad conceptual understandings of the term sustainability and its relation to the environmental impacts of DTs, in practice, environmental sustainability tends to be associated with technology based and carboncentric approaches. While narrowing conceptual understandings of environmental sustainability was viewed to have a practical purpose, it hid broader sustainability concerns. We urge those in the field not to lose sight of the wider ‘ethos of sustainability’.


23 April 2021 in Critical Public Health
Verified
Journal Article
Open access
GSgabrielle samuel
gabrielle samuel
SRStephen L Roberts
Stephen L Roberts
AFA. Fiske
A. Fiske
FLFederica Lucivero
Federica Lucivero
SMStuart McLennan
Stuart McLennan
SJS. B. Johnson
S. B. Johnson
In order to combat the COVID-19 pandemic, policymakers around the globe have increasingly invested in digital health technologies to support the ‘test, track and trace’ approach of containing the spread of the novel coronavirus. These technologies include mobile ‘contact tracing’ applications (apps), which can trace individuals likely to have come into contact with those who have reported symptoms or tested positive for the virus and request that they self-isolate. This paper takes a critical public health perspective that advocates for ‘genuine participation’ in public health interventions and emphasises the need to take citizen’s knowledge into account during public health decision-making. In doing so, it presents and discusses the findings of a UK interview study that explored public views on the possibility of using a COVID-19 contact-tracing app public health intervention at the time the United Kingdom (UK) Government announced their decision to develop such a technology. Findings illustrated interviewees’ range and degree of understandings, misconceptions, and concerns about the possibility of using an app. In particular, concerns about privacy and surveillance predominated. Interviewees associated these concerns much more broadly than health by identifying with pre-existent British national narratives associated with individual liberty and autonomy. In extending and contributing to ongoing sociological research with public health, we argue that understanding and responding to these matters is vital, and that our findings demonstrate the need for a forward-looking, anticipatory strategy for public engagement as part of the responsible innovation of the COVID-19 contact-tracing app in the UK.

6 September 2017 in New Genetics and Society
Verified
Journal Article
Open access
GSgabrielle samuel
gabrielle samuel
BFBobbie Farsides
Bobbie Farsides
The UK’s 100,000 Genomes Project has the aim of sequencing 100,000 genomes from UK National Health Service (NHS) patients while concomitantly transforming clinical care such that whole genome sequencing becomes routine clinical practice in the UK. Policymakers claim that the project will revolutionize NHS care. We wished to explore the 100,000 Genomes Project, and in particular, the extent to which policymaker claims have helped or hindered the work of those associated with Genomics England – the company established by the Department of Health to deliver the project. We interviewed 20 individuals linked to, or working for Genomics England. Interviewees had double-edged views about the context within which they were working. On the one hand, policymakers’ expectations attached to the venture were considered vacuous “genohype”; on the other hand, they were considered the impetus needed for those trying to advance genomic research into clinical practice. Findings should be considered for future genomes projects.

18 March 2021 in Journal of Empirical Research on Human Research Ethics
Verified
Journal Article
Open access
PDF file
GSgabrielle samuel
gabrielle samuel
JCJenn Chubb
Jenn Chubb
GDGemma Derrick
Gemma Derrick
The governance of ethically acceptable research in higher education institutions has been under scrutiny over the past half a century. Concomitantly, recently, decision makers have required researchers to acknowledge the societal impact of their research, as well as anticipate and respond to ethical dimensions of this societal impact through responsible research and innovation principles. Using artificial intelligence population health research in the United Kingdom and Canada as a case study, we combine a mapping study of journal publications with 18 interviews with researchers to explore how the ethical dimensions associated with this societal impact are incorporated into research agendas. Researchers separated the ethical responsibility of their research with its societal impact. We discuss the implications for both researchers and actors across the Ethics Ecosystem.

1 March 2018 in Journal of Medical Ethics
Verified
Journal Article
Open access
PDF file
SDSandi Dheensa
Sandi Dheensa
GSgabrielle samuel
gabrielle samuel
ALAnneke Lucassen
Anneke Lucassen
BFBobbie Farsides
Bobbie Farsides
Clinical practice and research are governed by distinct rules and regulations and have different approaches to, for example, consent and providing results. However, genomics is an example of where research and clinical practice have become codependent. The 100 000 genomes project (100kGP) is a hybrid venture where a person can obtain a clinical investigation only if he or she agrees to also participate in ongoing research—including research by industry and commercial companies. In this paper, which draws on 20 interviews with professional stakeholders involved in 100kGP, we investigate the ethical issues raised by this project’s hybrid nature. While some interviewees thought the hybrid nature of 100kGP was its vanguard, interviewees identified several tensions around hybrid practice: how to decide who should be able to participate; how to determine whether offering results might unduly influence participation into wide-ranging but often as yet unknown research and how to ensure that patients/families do not develop false expectations about receiving results. These areas require further debate as 100kGP moves into routine healthcare in the form of the national genomic medicine service. To address the tensions identified, we explore the appropriateness of Faden et al.’s framework of ethical obligations for when research and clinical care are completely integrated. We also argue that enabling ongoing transparent and trustworthy communication between patients/families and professionals around the kinds of research that should be permitted in 100kGP will help to understand and ensure that expectations remain realistic. Our paper aims to encourage a focused discussion about these issues and to inform a new ‘social contract’ for research and clinical care in the health service.